Literature DB >> 27150390

Gene Editing for Treatment of Neurological Infections.

Martyn K White1, Rafal Kaminski1, Hassen Wollebo1, Wenhui Hu1, Thomas Malcolm2, Kamel Khalili3.   

Abstract

The study of neurological infections by viruses defines the field of neurovirology, which has emerged in the last 30 years and was founded upon the discovery of a number of viruses capable of infecting the human nervous system. Studies have focused on the molecular and biological basis of viral neurological diseases with the aim of revealing new therapeutic options. The first studies of neurovirological infections can be traced back to the discovery that some viruses have an affinity for the nervous system with research into rabies by Louis Pasteur and others in the 1880s. Today, the immense public health impact of neurovirological infections is illustrated by diseases such as neuroAIDS, progressive multifocal leukoencephalopathy, and viral encephalitis. Recent research has seen the development of powerful new techniques for gene editing that promise revolutionary opportunities for the development of novel therapeutic options. In particular, clustered regulatory interspaced short palindromic repeat-associated 9 system provides an effective, highly specific and versatile tool for targeting DNA viruses that are beginning to allow the development of such new approaches. In this short review, we discuss these recent developments, how they pertain to neurological infections, and future prospects.

Entities:  

Keywords:  CRISPR/Cas9; Gene editing; NeuroAids; Neurological infections; Progressive multifocal encephalopathy

Mesh:

Year:  2016        PMID: 27150390      PMCID: PMC4965407          DOI: 10.1007/s13311-016-0439-1

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  71 in total

Review 1.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

2.  Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Authors:  F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

Review 3.  Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy.

Authors:  Jennifer L Gori; Patrick D Hsu; Morgan L Maeder; Shen Shen; G Grant Welstead; David Bumcrot
Journal:  Hum Gene Ther       Date:  2015-07       Impact factor: 5.695

4.  Rational design of a split-Cas9 enzyme complex.

Authors:  Addison V Wright; Samuel H Sternberg; David W Taylor; Brett T Staahl; Jorge A Bardales; Jack E Kornfeld; Jennifer A Doudna
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

Review 5.  TALEN-mediated genome editing: prospects and perspectives.

Authors:  David A Wright; Ting Li; Bing Yang; Martin H Spalding
Journal:  Biochem J       Date:  2014-08-15       Impact factor: 3.857

6.  Characterization of genomic deletion efficiency mediated by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells.

Authors:  Matthew C Canver; Daniel E Bauer; Abhishek Dass; Yvette Y Yien; Jacky Chung; Takeshi Masuda; Takahiro Maeda; Barry H Paw; Stuart H Orkin
Journal:  J Biol Chem       Date:  2014-06-06       Impact factor: 5.157

7.  The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I.

Authors:  J E Kaplan; M Osame; H Kubota; A Igata; H Nishitani; Y Maeda; R F Khabbaz; R S Janssen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

8.  Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems.

Authors:  Sergey Shmakov; Omar O Abudayyeh; Kira S Makarova; Yuri I Wolf; Jonathan S Gootenberg; Ekaterina Semenova; Leonid Minakhin; Julia Joung; Silvana Konermann; Konstantin Severinov; Feng Zhang; Eugene V Koonin
Journal:  Mol Cell       Date:  2015-10-22       Impact factor: 17.970

9.  CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus.

Authors:  HyunJun Kang; Petra Minder; Mi Ae Park; Walatta-Tseyon Mesquitta; Bruce E Torbett; Igor I Slukvin
Journal:  Mol Ther Nucleic Acids       Date:  2015-12-15       Impact factor: 10.183

Review 10.  CRISPR/Cas9 and cancer targets: future possibilities and present challenges.

Authors:  Martyn K White; Kamel Khalili
Journal:  Oncotarget       Date:  2016-03-15
View more
  5 in total

Review 1.  Novel AIDS therapies based on gene editing.

Authors:  Kamel Khalili; Martyn K White; Jeffrey M Jacobson
Journal:  Cell Mol Life Sci       Date:  2017-02-16       Impact factor: 9.261

2.  Sepsis in the era of data-driven medicine: personalizing risks, diagnoses, treatments and prognoses.

Authors:  Andrew C Liu; Krishna Patel; Ramya Dhatri Vunikili; Kipp W Johnson; Fahad Abdu; Shivani Kamath Belman; Benjamin S Glicksberg; Pratyush Tandale; Roberto Fontanez; Oommen K Mathew; Andrew Kasarskis; Priyabrata Mukherjee; Lakshminarayanan Subramanian; Joel T Dudley; Khader Shameer
Journal:  Brief Bioinform       Date:  2020-07-15       Impact factor: 11.622

Review 3.  A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System.

Authors:  Anna Bellizzi; Nicholas Ahye; Gauthami Jalagadugula; Hassen S Wollebo
Journal:  J Neuroimmune Pharmacol       Date:  2019-09-11       Impact factor: 4.147

Review 4.  CRISPR Editing Technology in Biological and Biomedical Investigation.

Authors:  Martyn K White; Rafal Kaminski; Won-Bin Young; Pamela C Roehm; Kamel Khalili
Journal:  J Cell Biochem       Date:  2017-07-04       Impact factor: 4.429

5.  Antiepileptogenesis and disease modification: Progress, challenges, and the path forward-Report of the Preclinical Working Group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop.

Authors:  Aristea S Galanopoulou; Wolfgang Löscher; Laura Lubbers; Terence J O'Brien; Kevin Staley; Annamaria Vezzani; Raimondo D'Ambrosio; H Steve White; Harald Sontheimer; John A Wolf; Roy Twyman; Vicky Whittemore; Karen S Wilcox; Brian Klein
Journal:  Epilepsia Open       Date:  2021-05-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.